Abstract
Acute myeloid leukaemia (AML) in the undifferentiated form can be a challenging. The prognosis of patients with AML- M0 is remarkably poor as compared to other WHO/FAB (French-American-British) subtypes. Conventional combination chemotherapy yields disappointing results. The reason for this may be the convergence of various unfavourable prognostic factors such as the high incidence of cytogenetic abnormalities, lack of differentiation features and the expression of immature markers such as CD34 and CD7 and the frequent expression of P-170 [1]. There are reports of a high frequency of mutations of AML1 gene in AML M0. Patients with AML1 mutations showed significantly higher leucocyte counts and higher marrow blast percentage, suggesting that this mutation is associated with greater cell proliferation, higher incidence of HLA-DR expression and higher frequency of IgH or T cell receptor (TCR) gene rearrangement [2]. Although many cases of acute myeloid leukaemias can be correctly identified morphologically with or without enzyme cytochemical analysis, immunophenotyping remains indispensable for proper identification of myeloid lineage in AML M0 [3]. We present a case of AML to highlight the problems encountered in diagnosis and management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.